Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial

@article{Volc2020SafetyAI,
  title={Safety and immunogenicity of the $\alpha$-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial},
  author={D. Volc and W. Poewe and A. Kutzelnigg and P. L{\"u}hrs and C. Thun-Hohenstein and A. Schneeberger and G. Galabova and N. Majbour and N. Vaikath and O. El-Agnaf and D. Winter and E. Mihailovska and A. Mairhofer and C. Schwenke and G. Staffler and R. Medori},
  journal={The Lancet Neurology},
  year={2020},
  volume={19},
  pages={591-600}
}
BACKGROUND Robust evidence supports the role of α-synuclein pathology as a driver of neuronal dysfunction in Parkinson's disease. PD01A is a specific active immunotherapy with a short peptide formulation targeted against oligomeric α-synuclein. This phase 1 study assessed the safety and tolerability of the PD01A immunotherapeutic in patients with Parkinson's disease. METHODS We did a first-in-human, randomised, phase 1 study of immunisations with PD01A, followed by three consecutive study… Expand
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
TLDR
PD03 and Anle138b can selectively target oligomeric α-synuclein, resulting in attenuation of neurodegeneration in the PLP-α-syn mice, and both approaches are potential therapies that should be developed further for disease modification in α- synucleinopathies. Expand
Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions
TLDR
This work summarizes immunotherapeutic approaches that were tested in pre-clinical or clinical studies in the last two decades in an attempt to treat Parkinson’s disease and suggests antibodies targeting extra- or intracellular alpha-synuclein could be efficient in limiting the aggregation and transmission. Expand
Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies.
The protein alpha-Synuclein (α-Syn) is a key contributor to the etiology of Parkinson's disease (PD) with aggregation, trans-neuronal spread, and/or depletion of α-Syn being viewed as crucial eventsExpand
Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.
  • A. Hung, M. Schwarzschild
  • Medicine
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
  • 2020
TLDR
Recent and ongoing clinical trials employing novel strategies toward disease modification, including those targeting alpha-synuclein and those repurposing drugs approved for other indications are reviewed. Expand
Therapeutic innovation in Parkinson’s disease: a 2020 update on disease-modifying approaches
TLDR
This review concentrates on new therapeutics – excluding cell and gene therapies – under investigation for PD with ‘disease-modifying’ potential, where the main preclinical and clinical data available are provided. Expand
α-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease.
TLDR
Individuals with SNCA, DJ-1, LRRK2, or GBA mutations have substantial intraneuronal α-syn deposition in sympathetic noradrenergic nerves in skin biopsies, whereas those with biallelic PRKN mutations do not. Expand
Soluble α-synuclein–antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia
TLDR
This work shows that αSyn activates the NLRP3 inflammasome in human induced pluripotent stem cell (hiPSC)-derived microglia (hiMG) via dual stimulation involving Toll-like receptor 2 (TLR2) engagement and mitochondrial damage, and finds that misfolded proteins such as αSyn and Aβ, when bound to antibody and presented to hiMG, result in enhanced proinflammatory response of the NL RP3 infammasome. Expand
New hopes for disease modification in Parkinson's Disease
TLDR
Various approaches currently pursued in the quest of disease modification in PD are summarized to offer hope that a breakthrough towards modifying the course of PD might be reached. Expand
Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model
TLDR
It is found that the random forest (RF) was the best classifier to separate different dementia syndromes and the developed LDA model with the RF classifier can assist clinicians in distinguishing variable neurodegenerative disorders. Expand
Current experimental disease-modifying therapeutics for multiple system atrophy
Multiple system atrophy (MSA) is a challenging neurodegenerative disorder with a difficult and often inaccurate early diagnosis, still lacking effective treatment. It is characterized by a highlyExpand
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial
TLDR
Single and multiple doses of PRX002 were generally safe and well tolerated and resulted in robust binding of peripheral &agr;-synuclein and dose-dependent increases ofPRX002 in cerebrospinal fluid, reaching cerebro Spinal fluid concentrations that may be expected to engage extracellular aggregated aggregated synuclein in the brain. Expand
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
TLDR
The combination of CSF o-/t- α-syn, p-S129-α-syn and p-tau provided the best fitting predictive model for discriminating PD patients from controls and correlated significantly with the severity of PD motor symptoms. Expand
Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.
TLDR
An overview on immunotherapeutic advances for neurodegenerative disorders, with special emphasis on α-synucleinopathies is provided, suggesting that immunotherapy might be a promising therapeutic approach for neuro degenerative diseases that progress with the accumulation and propagation of toxic protein aggregates. Expand
Immunotherapy in Parkinson’s disease: Current status and future directions
TLDR
The current status of development for immunotherapies in PD is discussed as well as the primary challenges that must be hurdled to bring an effective immunotherapeutic drug to market. Expand
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
TLDR
It is demonstrated that antibodies against the CT of α-syn reduce levels of CT-truncated fragments of the protein and its propagation, thus ameliorating PD-like pathology and improving behavioral and motor functions in a mouse model of this disease. Expand
Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials
TLDR
A large library of peptides that mimic the C-terminus region of α-syn were screened and a novel set of AFF that identified α- syn oligomers were discovered, which supported the efficacy of this novel active vaccination approach for synucleinopathies. Expand
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
TLDR
It is suggested that vaccination is effective in reducing neuronal accumulation of halpha-syn aggregates and that further development of this approach might have a potential role in the treatment of LBD. Expand
Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.
TLDR
The role of α-syn and modified forms of this protein in the initiation of innate and adaptive immune responses is examined and may reveal novel targets for neuroprotective interventions. Expand
Parkinson disease
TLDR
One of the greatest current challenges is to identify markers for prodromal disease stages, which would allow novel disease-modifying therapies to be started earlier. Expand
Therapeutic approaches to target alpha-synuclein pathology
TLDR
It is concluded that alpha-synuclein remains one of the most compelling therapeutic targets for Parkinson's disease, and related synucleinopathies, and that the multitude of approaches being tested provides hope for the future. Expand
...
1
2
3
...